Lundbeck has entered into an agreement to purchase Alder BioPharmaceuticals
for almost USD 2 Billion.
Lundbeck is a global
pharmaceutical firm developing and advancing the pipeline for brain diseases. The
company’s products are targeted at the disease areas within psychiatry and
neurology. For moving forward to realize its aim, Lundbeck is buying Alder
BioPharmaceuticals, a clinical-stage biopharmaceutical company transforming
migraine treatment.
The buyout will let Alder have an upfront offer of USD 18.00 per share in cash, along with one non-tradeable Contingent Value Right (CVR), authorizing it to have an additional USD 2.00 per share upon approval of eptinezumab by the European Medicines Agency (EMA).
The transaction is valued at up
to USD 1.95 billion, net of cash.
According to the Migraine Trust
Organization, globally Migraine is considered the 7th most disabling disease among
all diseases (responsible for 2.9% of all years of life lost to
disability/YLDs) and the leading cause of disability among all neurological
disorders.
Many medications are available to
treat migraine and the choice depends on the severity and frequency of headaches.
After the approval of Erenumab and Fremanezumab, several more studies are needed to fully understand the clinical potential, long-term safety, and cost-effectiveness of these therapies. Key players, such as Axsome Therapeutics, IMPAX Laboratories, Inc., Impel NeuroPharma, Zosano Pharma Corporation, Biohaven Pharmaceuticals, Inc., Allergan, and many others are involved in developing therapies for Migraine.
Expected launch of emerging therapies, such as INP104 (Impel NeuroPharma), AXS-07 (Axsome Therapeutics), M207/ADAM Zolmitriptan (Zosano Pharma Corporation), Rimegepant (Biohaven Pharmaceuticals), Ubrogepant (Allergen), etc. are expected to create a noticeable increase in the Migraine market size in the upcoming years.
Helsinn and Mundipharma China Pharmaceutical recently have received the
National Medical Products Administration’s approval of the oral formulation of Akynzeo
in China.
The FDA recommended the use of Akynzeo IV (netupitant/pelonosetron) in combination with dexamethasone in adults for the treatment of chemotherapy-induced nausea and vomiting (CINV).
Under the terms of the agreement, Mundipharma China Pharmaceutical will have exclusive marketing, promotion and sale rights and Helsinn will undertake the task of supplying the drug to Mundipharma. Also, the latter will be involved in co-detailing the product in Shanghai while retaining all international development rights, including clinical development activities.
Chemotherapy-Induced Nausea and Vomiting is one of the most distressing adverse effects of chemotherapy, and a primary factor for the discontinuation of the chemotherapy cycles leading to poor patient compliance.
The expected launch of other emerging therapies such as APD403 (Acacia Pharma) will change the treatment landscape of Chemotherapy-Induced Nausea and Vomiting during the forecast period [2019-2028].
